From Launch To IPO In 13 Months: Gossamer Bio CEO Says She s Running Company Of Her Dreams

Get the Full StoryImmunology-focused biotech startup Gossamer Bio has its market debut, with a lead drug candidate targeting moderate-to-severe asthma.

Share: